2025年前三季度，药明康德实现营业收入328.57亿元，同比增长18.61%，增速在全球医药外包行业中依然亮眼。然而，就在这份成绩单背后，是公司净利润率持续徘徊在20%左右，远低于国际龙头三星生物的30%以上，也低于国内同行凯莱英在细分领域的利润水平。规模在涨，利润却未同步起舞，这正是药明康德当前最真实的写照。与三星生物在生物药CDMO领域的咄咄逼人、赛默飞通过并购构建的“仪器+服务”超级平台...
Source Link2025年前三季度，药明康德实现营业收入328.57亿元，同比增长18.61%，增速在全球医药外包行业中依然亮眼。然而，就在这份成绩单背后，是公司净利润率持续徘徊在20%左右，远低于国际龙头三星生物的30%以上，也低于国内同行凯莱英在细分领域的利润水平。规模在涨，利润却未同步起舞，这正是药明康德当前最真实的写照。与三星生物在生物药CDMO领域的咄咄逼人、赛默飞通过并购构建的“仪器+服务”超级平台...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.